|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study showed that blockade of the CXCR4-CXCL12 axis by ulocuplumab is safe with acceptable AEs and leads to a high response rate in combination with lenalidomide and dexamethasone in patients with relapsed/refractory myeloma, making CXCR4 inhibitors a promising class of antimyeloma drugs that should be further explored in clinical trials.
|
31672767 |
2020 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, MM cells cultured on MM-MSCs' ECM displayed activated MAPK/TI, proliferation, EMT, and CXCR4 (↑15%-250%, P < 0.05).
|
30738861 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sensitivity of MM cell lines and primary CD138+ cells from MM patients to panobinostat correlated with reduced expression of the chemokine receptor CXCR4, whereas overexpression of CXCR4 in MM cell lines increased their resistance to panobinostat.
|
31325448 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data demonstrated that hypoxic stimulation in MM cell lines induced the overexpression of lncH19, which, in turn, is required for the expression of the hypoxia induced genes involved in MM dissemination, such as C-X-C Motif Chemokine Receptor 4 (CXCR4) and Snail.
|
30781795 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The chemokine (CXCR-4) receptor analogues are the newer agents being postulated for myeloma imaging and have shown good diagnostic performance.
|
30985424 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The decrease tumorigenicity correlated with a "more normal" PC immunophenotype in patients with MM and correlated with CD45 expression and a stronger expression of CXCR4.
|
31534632 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The α4β1 integrin and the chemokine receptor CXCR4 are key molecules for MM, ALL, and CLL cell trafficking into and out of the BM.
|
30787933 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review highlights the role of CXCR4 along with its significant interacting partners as a mediator of MM pathogenesis and summarizes the targeted therapies carried out so far.
|
31372333 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plerixafor inhibits CXCR4, thus inducing the mobilization of hematopoietic stem/progenitor cells in lymphoma and multiple myeloma (MM) patients eligible for autologous stem cell transplantation (ASCT).
|
31768009 |
2019 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, this study was conducted to explore the effect of SDF-1/CXCR4 and interleukin-6 (IL-6) in MM cell adhesion-mediated chemoresistance.
|
30953364 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
BTK induces CAM-DR through regulation of CXCR4 degradation in multiple myeloma.
|
31396324 |
2019 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
F50067, a humanized anti-CXCR4 IgG1 antibody, has promising preclinical activity in MM.We present a phase I multicenter escalation study in relapsed/refractory MM (RRMM) to determine the maximum tolerated dose (MTD) for F50067 alone and in combination with lenalidomide and low dose dexamethasone (Len-Dex).
|
29844860 |
2018 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
AMD3100 (plerixafor), a small molecule that selectively inhibits the chemokine receptor CXCR4 is approved for mobilization in combination with G-CSF in patients with Non-Hodgkin's lymphoma and multiple myeloma.
|
27905003 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study assessed the diagnostic performance of the CXCR4-directed radiotracer [<sup>68</sup>Ga]Pentixafor in MM and a potential role for stratifying patients to CXCR4-directed therapies.
|
28042328 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
FTY720 in combination with bortezomib demonstrates superior tumor growth inhibition and abrogates bortezomib-induced CXCR4 increase on MM cells.<b>Conclusions:</b> Altogether, our work identifies a cross-talk between the S1P and CXCR4 pathways in MM cells and provides a preclinical rationale for the therapeutic application of FTY720 in combination with bortezomib in patients with MM.<i></i>.
|
27697999 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have recently reported promising first-in-man experience with CXCR4-directed endoradiotherapy (ERT) in multiple myeloma (MM).
|
28529638 |
2017 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plerixafor (P), an agent that selectively and reversibly binds to the chemokine receptor CXCR4, has been approved in combination with G-CSF (P + G-CSF) for stem cell (SC) mobilization in patients with multiple myeloma (MM).
|
27735212 |
2017 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We functionally overexpressed integrin-α8 in MM cell lines, and surprisingly, stemness features including HIF1α, VEGF, OCT4, and Nanog, as well as epithelial mesenchymal transition (EMT)-related phenotypes, including N-cadherin, Slug, Snail and CXCR4, were induced.
|
28008160 |
2016 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CXCR4 Regulates Extra-Medullary Myeloma through Epithelial-Mesenchymal-Transition-like Transcriptional Activation.
|
26190113 |
2015 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
CD49d, CD44, and CD184, are highly expressed in PCM.
|
23450831 |
2014 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Importantly, buparlisib enhanced MM cell mobilization in vivo which was driven by decreased adhesion of MM cells to BMSCs and increased chemotaxis via up-regulation of CXCR4 expression.
|
25060991 |
2014 |
|
Multiple Myeloma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All patients with the CXCR4 T allele and 16 out of 48 with wild type genotype presented with grade III of MM according to the International Staging System (ISS) (p=0.047).
|
23711392 |
2013 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The α4β1-dependent myeloma cell adhesion is up-regulated by the chemokine CXCL12, and pharmacological blockade of the CXCL12 receptor CXCR4 leads to defective myeloma cell homing to bone marrow (BM).
|
22711564 |
2013 |
|
Multiple Myeloma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data demonstrate BTK and cell-surface CXCR4 association in myeloma cells and that BTK plays a role in myeloma cell homing to bone and myeloma-induced bone disease.Am.J. Hematol.88:463-471, 2013.
|
23456977 |
2013 |
|
Multiple Myeloma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Peripheral and marrow iDCs from MM showed high CXCR4 expression and were augmented in bone marrow of MM patients with respect to monoclonal gammopathy of undetermined significance.
|
21569821 |
2011 |